HSD17B4 and prostate carcinoma: There is evidence that HSD17B4 is associated with a variety of cancers, including liver cancer, ovarian cancer, and prostate cancer, making it a potential therapeutic target (Ko et al., 2018; Lu et al., 2019; Nagayoshi et al., 2005).